Tech Company Financing Transactions
OrsoBio Funding Round
On 9/6/2024, OrsoBio landed $67 million in Series B funding from Ascenta Capital, Woodline Partners and Eli Lilly and Company.
Transaction Overview
Company Name
Announced On
9/6/2024
Transaction Type
Venture Equity
Amount
$67,000,000
Round
Series B
Investors
Ascenta Capital (Lead Investor) (Evan Rachlin)
Woodline Partners (Lead Investor)
Proceeds Purpose
Proceeds from the financing will be used to accelerate development of the Company's mitochondrial protonophore portfolio for the treatment of obesity and associated metabolic disorders.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
2671 Marshall Dr
Palo Alto, CA 94303
USA
Palo Alto, CA 94303
USA
Phone
Undisclosed
Website
Email Address
Overview
OrsoBio is a clinical-stage biopharmaceutical company that creates therapies for patients suffering from severe metabolic disorders such as diabetes, severe dyslipidemia, lipodystrophies, and others. OrsoBio is committed to restoring energy homeostasis in patients with severe metabolic disorders, in some cases, by targeting pathways relevant tomaintaining energy balance. OrsoBio revolutionizes the treatment of these disorders by addressing the underlying cause.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Mani Subramanian
Co-Founder
Gans Ganapati
Browse more venture capital transactions:
Prev: 9/6/2024: Fastn venture capital transaction
Next: 9/6/2024: Vanilla Finance venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. All VC database entries reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs